Investor Relations

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Investor Relations

KemPharm uses its LAT™ Technology to discover and develop prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.

 

Change
Volume
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary KemPharm to Present at the Benzinga Healthcare Small Cap Conference
CELEBRATION, Fla. , Sept. 27, 2021 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle , Ph.D., President and Chief Executive Officer of KemPharm , will present
Toggle Summary KemPharm to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
CELEBRATION, Fla. , Sept. 23, 2021 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle , Ph.D., President and Chief Executive Officer of KemPharm , will present
Toggle Summary KemPharm to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
CELEBRATION, Fla. , Sept. 09, 2021 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle , Ph.D., President and Chief Executive Officer of KemPharm , will present
Toggle Summary KemPharm Appoints Tamara A. Seymour to Board of Directors
CELEBRATION, Fla. , Aug. 18, 2021 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today the appointment of Tamara A. Seymour to serve on its Board of Directors and as Chair of the

View more

Upcoming Events

There are currently no events to display.

View more

Letter to Shareholders

Travis C. Mickle, Ph.D.
Chairman, President, Chief Executive Officer and Shareholder
KemPharm, Inc.

Download